Evidence map›Paper›PMID 21959306›Full record

ReviewDrug discovery today2012

Curcumin nanoformulations: a future nanomedicine for cancer.

Murali M Yallapu, Meena Jaggi, Subhash C Chauhan

Open access · greenAbstract readReview
In one paragraph

Review in Drug discovery today, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 2 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 2 syntheses or guidelines pooled it, 717 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Nanoencapsulation ofRSC advances · 2026
    Article

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Murali M YallapuCancer Biology Research Center, Sanford Research/University of South Dakota, 2301 E. 60th Street North, Sioux Falls, SD 57104, USA. Murali.Yallapu@sanfordhealth.org
Meena Jaggi
Subhash C Chauhan
Sanford Research · USUniversity of South Dakota · US

Funding

Aspects of MUC13 Mucin in CancerR01CA142736 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CHAUHAN, SUBHASH C. · 2010 to 2013
$1.2M
NCI NIH HHS R01 CA142736
6 · The paper itself

Abstract

Curcumin, a natural diphenolic compound derived from turmeric Curcuma longa, has proven to be a modulator of intracellular signaling pathways that control cancer cell growth, inflammation, invasion and apoptosis, revealing its anticancer potential. In this review, we focus on the design and development of nanoparticles, self-assemblies, nanogels, liposomes and complex fabrication for sustained and efficient curcumin delivery. We also discuss the anticancer applications and clinical benefits of nanocurcumin formulations. Only a few novel multifunctional and composite nanosystem strategies offer simultaneous therapy as well as imaging characteristics. We also summarize the challenges to developing curcumin delivery platforms and up-to-date solutions for improving curcumin bioavailability and anticancer potential for therapy.

Indexed as

AnimalsCurcuminDrug Delivery SystemsDrug DesignHumansNanomedicineNanoparticlesNeoplasmsCurcumin

Identifiers

PMID21959306
PMCPMC3259195
OpenAlexW2082225136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.